<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Temozolomide (TMZ) is an oral <z:chebi fb="0" ids="22333">alkylating agent</z:chebi> used during concurrent and adjuvant chemotherapy for newly diagnosed <z:hpo ids='HP_0100843'>glioblastoma</z:hpo> multiforme </plain></SENT>
<SENT sid="1" pm="."><plain>Temozolomide is generally well tolerated and improves survival; however, severe adverse events have occasionally been reported </plain></SENT>
<SENT sid="2" pm="."><plain>Here, we report the case of a patient who developed <z:hpo ids='HP_0001915'>aplastic anemia</z:hpo> with related complications in the setting of concurrent TMZ treatment with radiotherapy </plain></SENT>
<SENT sid="3" pm="."><plain>This case illustrates that <z:hpo ids='HP_0001915'>aplastic anemia</z:hpo> is a rare side effect of TMZ that can occur relatively early in the course of concurrent chemotherapy, and underscores the importance of clinician awareness of this potentially devastating side effect </plain></SENT>
</text></document>